Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L17 pseudogenes are DNA sequences in the human genome that share high sequence similarity with the functional ribosomal protein L17 gene but have lost protein-coding capability through mutations or truncations. Processed pseudogenes like these are generally considered molecular fossils, typically nonfunctional and not transcribed, although rare regulatory functions for some pseudogenes have been hypothesized. There are dozens of distinct ribosomal protein L17 pseudogene loci in the genome, none of which encode a functional ribosomal protein. These pseudogenes are not considered therapeutic targets, nor are they implicated in disease or drug interactions. The true, protein-coding therapeutic target is ribosomal protein L17 (RPL17), not its pseudogenes.
None (no mechanism of action due to lack of protein product or function)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L17 pseudogene (None in widespread use).